Relamorelin

Drug Profile

Relamorelin

Alternative Names: BIM-28131; BIM-28163; RM 131

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ipsen
  • Developer Allergan; Ipsen
  • Class Gastrokinetics; Growth hormone-releasing hormones; Peptides; Piperidines; Thiophenes
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetic gastroparesis
  • Phase II Constipation; Gastrointestinal disorders
  • Discontinued Cachexia

Most Recent Events

  • 29 Sep 2017 Phase-III clinical trials in Diabetic gastroparesis in USA (SC) (NCT03285308)
  • 02 Nov 2016 Efficacy data from a phase IIb trial in Diabetic gastroparesis released by Allergan
  • 27 Oct 2016 Allergan exercises its option to acquire Motus, and plans to complete the acquisition by the end of 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top